sotorasib,docetaxel
amgen,sanofi,aventis
['lumakras', 'lung', 'docetaxel', 'amgen']
amgen s lumakras cut the risk of disease progression or death by 34% compared with the docetaxel in previously treated kras g12c-mutated non-small cell lung cancer, according to an abstract released at the esmo 2022. lumakras is currently the only fda-approved kras inhibitor. 
Un peu de science et de santé et surtout sourire. 
Curieuse de tout. Adepte du second degré.
Tweets strictement personnels.